Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
By P. Tariot, M. Farlow, G. Grossberg, S. Graham, S. McDonald, I. Gergel. Journal of the American Medical Association (JAMA), 2004
1,393 citations recorded by the source corpus.
Subfields: Neurology, Physical Therapy, Sports Therapy and Rehabilitation, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/08baa827bdbec22857579e3b05c4e4a9ffec71bd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
In Physical Therapy, Sports Therapy and Rehabilitation
In Psychiatry and Mental health
Citations in the corpus
- Current and future treatments for Alzheimer’s disease (2013, background): “…groups of patients with moderate to severe AD showed a significant benefit in cognitive function, language, ADL, behaviors and global state from combination use of memantine and donepezil over the placebo group (memantine and placebo) [Tariot et al. 2004; Feldman et al.2006; Howard et al. 2012].”
- Therapeutics of Alzheimer's disease: Past, present and future. (2014, background): “A number of investigators have looked at the possible advantage of its combining memantine with AChEI in AD (Atri et al., 2013; Dantoine et al., 2006; Howard et al., 2012; Lopez et al., 2009; Porsteinsson et al., 2008; Riepe et al., 2007; Tariot et al., 2004).”
- Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond (2006, positive): “Another study reported that, in combination with donepezil (Aricept; Eisai/Pfizer), memantine treatment improved cognitive function to some degree in moderate-to-severe Alzheimer's patient”
- Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline (2007, methodology): “Two studies were performed in patients with moderate-to-severe AD (I) [168,169], one of them in patients on stable treatment with donepezil [169].”
- Does analysis using “last observation carried forward” introduce bias in dementia research? (2008, result): “, ones that result in higher dropout rates in treatment groups than in placebo groups), it is possible that last observation carried forward results in bias against memantine while favouring cholinesterase inhibitors.(15)”
- Donepezil and memantine for moderate-to-severe Alzheimer's disease. (2012, neutral): “3 to <6 mo 3 (4) 4 (5) 3 (4) 4 (5) 14 (5)”
- The neuropathogenesis of AIDS (2005, background): “155–157 ); it is now approved for therapy for Alzheimer's diseas”
- Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. (2007, methodology): “Memantine was approved several years ago for the treatment of mild-severe to severe AD (2002 EU, 2003 USA) and since this time is on the market in Europe, USA and many countries in the world.”
- Education and Dementia in the Context of the Cognitive Reserve Hypothesis: A Systematic Review with Meta-Analyses and Qualitative Analyses (2012, background): “Autopsy studies have found that 10% to 40% of individuals with mild to moderate brain pathology did not manifest clinical symptoms of dementia [9], [10].”